TL;DR
Kivo Health raised $10 million in a Series A round led by Allumia Ventures, bringing its total financing to $16 million. The Seattle company plans to expand its virtual home-care program for COPD nationwide and says it aims to reach tens of thousands of patients within two years.
Kivo Health, a Seattle-based virtual home-care startup focused on chronic lung diseases, has raised $10 million in Series A financing to support a nationwide expansion. The round brings the company’s total financing to $16 million and comes as it plans to extend its COPD program to more patients and, eventually, address other high-cost chronic illnesses.
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Allumia Ventures led the financing, with participation from Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures, according to Home Health Care News. Kivo said the new funding will help it expand nationally. The company has not disclosed a detailed rollout schedule or how the money will be allocated among expansion, hiring, technology and other needs.
Kivo’s current program targets chronic obstructive pulmonary disease (COPD). After enrollment, a patient receives a home kit that includes a tablet, an oxygen monitor and exercise bands. The patient meets virtually with a respiratory therapist for an assessment and an individualized care plan. Kivo’s website describes a nine-week program in which small groups meet with therapists online twice a week to practice breathing techniques, do targeted exercises and learn about managing COPD.
Co-founder and CEO Victor Sadauskas told Home Health Care News by email that Kivo has delivered tens of thousands of sessions and provided care to thousands of patients. He said the company plans to reach tens of thousands of patients over the next two years. Those figures and the company’s reported outcomes were not independently verified in the source report.
Funding Could Broaden Home COPD Care
The financing gives Kivo additional capital to take a therapist-led program delivered at home to a wider geographic area. For people managing COPD, the model is intended to provide support between regular clinical visits, rather than relying only on in-person appointments when symptoms worsen. The company says earlier intervention and ongoing coaching can improve quality of life and help prevent hospital stays.
Kivo also says its services can reduce spending for health plans by avoiding unnecessary hospitalizations, emergency-room visits and nursing-home days. The company claims savings of $8,245 per member per year, but the source report does not provide the study design, patient population, comparison group or other details needed to evaluate that estimate. The funding announcement signals investor backing for expansion; it does not by itself establish that the program produces those savings across patients or markets.
The company says its program is covered by Medicare, Medicaid and several major health plans, including UnitedHealthcare, Humana, Blue Cross, Aetna and Priority Health. Broader availability could matter to patients and providers seeking additional ways to support chronic disease management at home, though access may depend on coverage, eligibility and local service capacity.
Products Worth Considering

Garmin Forerunner 970 GPS Running and Triathlon Smartwatch, 47 mm, Carbon Gray DLC Titanium with Black/Whitestone Band

Hyperice Normatec Elite Wireless Compression Boots

Therabody Theragun Relief Massage Gun, 3-Speed, Navy
As an affiliate, we earn on qualifying purchases.
How Kivo Delivers COPD Support
Kivo describes its model as virtual home care combining technology with individual treatment plans. Patients use the supplied equipment and meet respiratory therapists remotely; group sessions include instruction and exercises. The program is designed to help people manage symptoms and care routines outside a clinic, with a specific focus on COPD rather than a broad range of conditions at present.
The company’s announced financing follows its earlier support from investors including Y Combinator, which also participated in this Series A round. The new round raises Kivo’s reported total financing to $16 million. Its longer-term plan is to adapt its care model for other high-cost chronic illnesses, but it has not named those conditions or given a timeline for launching additional programs.
“We have delivered tens of thousands of sessions, providing thousands of patients access to care that improves symptoms and saves health plans money by reducing unnecessary hospitalizations, ER visits and nursing home days.”
— Victor Sadauskas, Kivo Health co-founder and CEO, in an email to Home Health Care News
Expansion Details Remain Undisclosed
Kivo has not said which states or markets it will enter first, how quickly it expects to expand, or how the $10 million round will be spent. The company’s two-year patient target is an ambition stated by its CEO; the source report does not describe a rollout plan or provide current enrollment totals beyond the CEO’s general account of thousands of patients.
The reported clinical and financial benefits also need to be understood as company claims. The available source does not provide independent verification, detailed outcome measures or the methods behind the $8,245 annual savings estimate. It is also unclear which conditions Kivo will target after COPD, when any additional programs might launch, and whether existing insurance coverage will apply to those services.
National Rollout and New Conditions
Kivo’s stated next step is to expand its COPD program nationwide, with a goal of serving tens of thousands of patients over the next two years. The company has not announced locations, launch dates or interim enrollment milestones, so the pace and reach of that expansion remain to be seen.
The company has also said it intends to bring its care model to other high-cost chronic illnesses. Any next announcement would be expected to clarify which conditions it will pursue, how the programs will be structured and whether they will receive health-plan coverage. For now, the Series A funding supports an expansion plan, while its timeline and independently measured results remain open questions.
Key Questions
How much did Kivo Health raise?
Kivo raised $10 million in Series A financing, bringing its total financing to $16 million, according to Home Health Care News.
Who invested in the Series A round?
Allumia Ventures led the round. Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures also participated.
What care does Kivo provide?
Kivo currently focuses on virtual home care for COPD. Its program uses a home kit and remote respiratory-therapist sessions, including a nine-week course with twice-weekly small-group meetings, according to the company’s website.
What is Kivo’s expansion target?
CEO Victor Sadauskas told Home Health Care News that Kivo plans to expand nationwide and serve tens of thousands of patients in the next two years. The company has not published a market-by-market timeline.
Has Kivo independently demonstrated its claimed savings?
The company claims savings of $8,245 per member per year, but the source report does not provide independent verification or the methodology behind that figure. It should be treated as a company-reported estimate.
Source: homehealthcarenews.com
